ArticleEJNMMI reports2026
A case report of enduring benefit of sequential PRRT in malignant insulinoma.
Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 62-year-old woman diagnosed in 2015 with de novo metastatic malignant insulinoma. She presented severe hypoglycemia and was initially treated with somatostatin analogs, chemotherapy (capecitabine-temozolomide), and diazoxide, but none of these controlled the symptoms. Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTATATE was initiated in 2016, resulting in marked clinical and radiological responses after four cycles. Due to recurrence, two subsequent PRRT treatments were administered in 2021 and 2024, each consisting of two cycles, leading to significant improvements in symptoms and imaging findings. To date, the patient has undergone eight PRRT cycles with sustained biochemical and morphological responses, long-term glycemic control, and excellent tolerance. This case illustrates the long-term efficacy of sequential PRRT retreatment in refractory functional pancreatic neuroendocrine tumors (pNETs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.